Bionano Genomics, Inc.

Bionano Genomics, Inc., a San Diego-based for-profit manufacturer of optical genome mapping instruments and consumables, operates exclusively as a prime contractor to federal civilian agencies, with no federal grant or subcontractor footprint. The company does not hold SBA small business designations and competes in full-and-open procurements, with one exception: a $49,900 purchase order from the USDA Agricultural Research Service for an Ionic Purification System awarded under Total Small Business set-aside in August 2023. Bionano's business centers on selling specialized genomic analysis equipment — primarily the Saphyr System for structural variant detection — and associated reagent kits, software licenses, and purification systems that support molecular research and diagnostics at federal research institutions.

Bionano's customer base concentrates in biomedical research agencies within the Department of Health and Human Services. The NIH Clinical Center leads by volume (5 awards, $256 thousand combined potential value), followed by the CDC Pittsburgh (6 awards, $178 thousand), the NIH National Cancer Institute (2 awards, $503 thousand), and the USDA Agricultural Research Service (4 awards, $325 thousand). The top five customer entities account for 83 percent of recent awards. The funding rankings diverge slightly: while the NIH Clinical Center dominates by order count, the National Cancer Institute and the National Heart Lung and Blood Institute anchor the largest single-award dollars, reflecting the capital nature of Bionano's instrument sales. Representative prime work includes a $120 thousand firm fixed-price purchase order from the NIH Clinical Center in August 2024 for a Saphyr System buyout with ownership transfer, maintenance, software, and training; a $68.7 thousand award in February 2024 for BIONANO PREP genome mapping kits to support 12 human genomes; a $49.9 thousand CDC Pittsburgh purification system procurement in September 2023; and a $25.6 thousand NIH Clinical Center order in September 2025 for optical genome mapping reagents.

Activity has remained episodic across the past five years — one award in 2021, three in 2023, three in 2024, two in 2025, and one in 2026 — with combined potential value of $1.7 million but cumulative invoiced value of $21.3 million, signaling substantial order volume relative to stated contract ceilings. Two awards complete within the next twenty-four months (combined potential value $43 thousand), presenting a modest recompete window. Bionano's procurement category aligns with its manufacturing footprint: 11 awards fall under Analytical Laboratory Instrument Manufacturing (NAICS 334516), with 5 additional awards in Drugs and Biologicals and smaller tranches in instrument maintenance and in vitro diagnostic substances. The company owns a subsidiary, Purigen Biosystems, Inc., also registered as a for-profit manufacturer of goods, though the source does not specify capabilities or federal contracting activity distinct from the parent entity. Bionano's federal footprint reflects its role as a specialized life-sciences equipment vendor serving research-grade customers — no defense, IT services, or integration work appears in the award record.

Bionano systems provide essential genomic information no other technology can provide to help advance greater understanding of genome biology. Bionano's next-generation mapping combines proprietary NanoChannel arrays with optical mapping to image extremely long, high-molecular-weight DNA in its most native state.

This technology enables unparalleled structural variation sensitivity, genome assembly contiguity hundreds of times that of short-read sequencing alone and the accuracy to correct sequencing-based errors. Bionano genome mapping is advancing research across areas including human disease, agricultural bioengineering, and genome discovery.